Ervebo Vaccine

Ervebo Vaccine Latest News

Recently, the World Health Organisation and its partners said that Congo will receive 70,000 doses of the Ervebo vaccine.

About Ervebo Vaccine

• It is licensed for use against the Ebola virus disease.
• It is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (VSV) vaccine.
• Working
  • The vaccine only contains one protein from the Zaire Ebola virus and cannot cause Ebola virus disease.
  • When a person receives the vaccine, it triggers an immune response against this viral protein. 
• Administration: It is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease. 
• It is manufactured by Merck.
• It does not provide protection against other species of orthoebolaviruses or orthomarburgviruses.

Key Facts about Ebola

• It is a severe and often deadly viral disease caused by a group of viruses known as orthoebolaviruses (formerly ebolavirus).
• It is a severe contagious disease affecting humans and non-human primates. 
• Ebola, first identified in 1976 in southern Sudan and the Democratic Republic of Congo, primarily affects remote villages in Central and West Africa.  
• It is known as a hemorrhagic fever virus because it can cause problems with the clotting system of the body and lead to internal bleeding as blood leaks from small blood vessels.
• Transmission
  • The virus is transmitted to people from wild animals (such as fruit bats, porcupines, and non-human primates).
  • It then spreads in the human population through direct contact with the blood, secretions, organs, or other bodily fluids of infected people and with surfaces and materials contaminated with these fluids.
  • Ebola cannot be transmitted by air.
• Symptoms
  • Incubation period: Typically 5 to 15 days; range is 2 to 21 days. 
  • Symptoms include fever, diarrhea, vomiting, bleeding, and often, death.

Source: IT

‹ ›